본문 바로가기
  • Home

An outpatient case study of Cyaplex F: mitigated adverse effects associated with Imatinib

  • CELLMED
  • Abbr : CellMed
  • 2023, 13(12), pp.1-7
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : September 27, 2023
  • Accepted : September 27, 2023
  • Published : September 30, 2023

Sun L Riehm 1

1Indiana University Health

Irregular Papers

ABSTRACT

Objective: A case of reducing adverse effects associated with imatinib using Cyaplex F. Methods: The 52-year-old female with past medical history of stage 1 triple-positive breast cancer 10 years ago, and current metastatic melanoma has been complaining adverse effects after imatinib was started. Results: After OCNT was initiated, the patient’s headache and muscle pain have been much tolerable and her AST/CPK levels were returned close to her baseline. Conclusion: OCNT may reduce side effects caused by Imatinib and help patient to stay with the current chemotherapy regimen.

Citation status

* References for papers published after 2022 are currently being built.